Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Research

| More

Q4FY21 Result Update - Ajanta Pharmaceuticals - ICICI Direct

Posted On: 2021-05-02 02:42:33 (Time Zone: UTC)


Q4 revenues grew 11.0% YoY to Rs. 757 crore. Domestic sales grew 23.2% to Rs. 218 crore whereas emerging markets (branded) de-grew 10.5% YoY to Rs. 273 crore amid logistical challenges in Asia and Africa. US sales grew 21% to Rs. 173 crore. Africa tender business grew 86% YoY to Rs. 80 crore. EBITDA margins improved significantly to 34.3% (vs. 22.2% in Q4FY20) amid better gross margins and lower other expenditure. EBITDA grew 71.4% YoY to Rs. 259 crore. PAT grew 21% YoY to Rs. 159 crore. Delta vis--vis EBITDA was mainly due to lower other income and higher tax rate.

Valuation & Outlook

Q4 revenue was mostly in-line with expectations, albeit skewed. Profitability was better-than-expected due to lower-than-expected other expenses leading to a strong margin performance. The management expects to continue to outperform the market in the Branded Generic space, in domestic and export markets both. We expect the US to maintain its 20% growth momentum, going ahead. On the margin front, we expect Ajanta's performance to remain stable at +30% with the current run-rate of other expenses (the new base) to be moderated by slightly higher spend on R&D and increased MR activity. Overall, calculated focus, healthy margins, return profile and lighter balance sheet are some key differentiators for Ajanta. The company remains a play on global branded generics space. We maintain BUY rating and arrive at our target price of Rs. 2250 (unchanged) based on 24x FY23E EPS of ~Rs. 93.8.

For details, click on the link below: https://www.icicidirect.com/mailimages/IDirect_AjantaPharma_Q4FY21.pdf

Shares of AJANTA PHARMA LTD. was last trading in BSE at Rs.1834 as compared to the previous close of Rs. 1890.2. The total number of shares traded during the day was 12717 in over 1277 trades.

The stock hit an intraday high of Rs. 1932.45 and intraday low of 1826.75. The net turnover during the day was Rs. 23641029.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.


Other Headlines:

Maintain BUY on CreditAccess Grameen - Accelerated write-offs dents earnings - HDFC Securities

Sundram Fasteners Q4 Results Review - HDFC Securities

SRF - Specialty Chemicals continues to shine! - HDFC Securities

Realtors welcome RBI latest stance, expect relief initiatives in next announcement

CreditAccess Grameen - Q4FY21 Result Update - ICICI Securities

JM Financial - Exits FY21 with well contained stress pool; sequential AUM uptick encouraging - ICICI Securities

Hero MotoCorp - Margins remain resilient - ICICI Securities

CEAT - Margin pressures likely to intensify - ICICI Securities

SRF Limited - FY22E growth capped on higher plants utilisation - ICICI Securities

I-direct Instinct - Automotive Axles - ICICI Direct

Quant Pick - Axis Bank - ICICI Direct

Gladiator Stocks - Caplin Point Laboratories - ICICI Direct

Q4FY21 Result Update - Coforge Ltd - ICICI Direct

Tata Consumer Products - Q4FY21 First Cut - ICICI Direct

Coforge Ltd - Q4FY21 Result Update - YES Securities

CreditAccess Grameen - Q4FY21 Result Update - YES Securities

Blue Star - Q4 FY21 first cut - Inline performance - YES Securities

Tata Consumer - 4QFY21 results first cut - YES Securities

Tata Consumer 4QFY21 results first cut - YES Securities

Maintain BUY on CDSL - Strong growth momentum - HDFC Securities

Maintain ADD on L&T Infotech - Steady progression - HDFC Securities

Blue Dart Express - Q4FY21 - The bulge continues - ICICI Securities

Tata Steel - FY22E Net Debt/EBITDA at <1x - ICICI Securities

Larsen & Toubro Infotech - Consistency continues! - ICICI Securities

CEAT - Decent quarter; new capex likely to curtail FCF - ICICI Securities

Q4FY21 Result Update - Alembic Pharma - ICICI Direct

Gladiator Stocks - Cadila Healthcare - ICICI Direct

Q4FY21 Result Update - Larsen & Toubro Infotech - ICICI Direct

RBI Action Update - May 2021 - ICICI Direct

Quant Pick - Aurobindo Pharma - ICICI Direct

Q4FY21 Result Update - Greaves Cotton - ICICI Direct

Adani Total Gas Ltd - Q4FY21 Result Update - YES Securities

L&T Infotech - Q4FY21 Result Update - YES Securities

Bluedart Express - Q4 FY21 first cut - Miss on topline; Profitability improves - YES Securities

Views on the announcement by RBI Governor - Ms. Bekxy Kuriakose, Head - Fixed Income, Principal Asset Management

Views from experts on RBI announcement - May 5, 2021

Maintain REDUCE on RBL Bank - Elevated retail slippages continue - HDFC Securities

Resolution 2.0 measure by RBI to provide relief to real estate linked SME stakeholders

Godrej Properties - Robust quarter; positives fairly priced in - HDFC Securities

RBI Relief 2.0 - May 2021 - Acuité Ratings & Research

MDF Industry - Countervailing duty on MDF recommended; imports may get hit structurally - ICICI Securities

Home First Finance Company - Core earnings steady; profitability buoyed by securitisation income - ICICI Securities

RBL Bank - Modest return profile in the interim; transitioning underway - ICICI Securities

Alembic Pharmaceuticals - US continues to be under pressure - ICICI Securities

Q4FY21 Result Update - SBI Life Insurance - ICICI Direct

Q1CY21 Result Update - Varun Beverages - ICICI Direct

RBL Bank: Views from leading research houses on Q4FY21 results

Q4FY21 Result Update - Supreme Industries - ICICI Direct

Q4FY21 Result Update - Tata Chemicals - ICICI Direct

Larsen & Toubro Infotech - Q4FY21 First Cut - ICICI Direct


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020